| Title | Antiphospholipid syndrome. | | Author(s) | George D, Erkan D | | Institution | Department of Rheumatology, Yale School of Medicine, New Haven, CT 06520, USA. dtg24@pantheon.yale.edu | | Source | Prog Cardiovasc Dis 2009 Sep-Oct; 52(2):115-25. | | MeSH | Antibodies, Antiphospholipid
Antiphospholipid Syndrome
Aspirin
Comorbidity
Female
Humans
Lupus Coagulation Inhibitor
Myocardial Infarction
Platelet Aggregation Inhibitors
Pregnancy
Pregnancy Complications
Pregnancy Outcome
Thrombosis
| | Abstract | The antiphospholipid syndrome (APS) is an autoimmune systemic disease that is diagnosed when there is vascular thrombosis and/or pregnancy morbidity occurring with persistently positive antiphospholipid antibodies (aPL) (lupus anticoagulant test, anticardiolipin antibodies, and/or anti-beta(2)-glycoprotein I antibodies). Although International APS Classification Criteria have been formulated to provide a uniform approach to APS research, aPL may cause a spectrum of clinical manifestations, some of which are not included in these criteria. The main aPL-related cardiac manifestations include valve abnormalities (vegetations and/or thickening), myocardial infarction (MI), intracardiac thrombi, and myocardial microthrombosis. In this article, we will review the definition, etiopathogenesis, clinical manifestations, diagnosis, and treatment of aPL-related clinical events with emphasis on cardiac manifestations. | | Language | eng | | Pub Type(s) | Journal Article
Review
| | PubMed ID | 19732604 |
|
